TSXV:RXPharmaceuticals
BioSyent (TSXV:RX) Stock Tracks Revenue Surge Against Slower Profit Growth
BioSyent stock came into this earnings print with a strong recent run, up about 14.6% over the past three months and closing at CA$15.70 on 21 August. The market has been paying for growth, and Q2 delivered exactly that headline: revenue of CA$19.9m and basic earnings per share of CA$0.25. For a specialty pharma company that lives and dies on product uptake and operating discipline, this quarter was about one thing above all: a stronger profit pulse, with net income of CA$2.8m setting the...